Depressive disorders and their correction in complex treatment of metabolic syndrome patients
Abstract
Aim. To study clinical and metabolic effects of selective serotonin re‑uptake inhibitor (SSTI) sertraline in complex treatment of metabolic syndrome (MS) patients.
Material and methods. Thirty‑six MS patients were divided into two groups, according to treatment program and psychological symptoms. Intervention group received basic therapy and, in case of depressive disorders (DD) diagnosed, sertraline (50 mg/d), once per day in the morning, for 8 weeks. Control group received basic therapy only. In all participants, clinical, biochemical, and psycho‑physiological parameters were assessed.
Results. DD of varying severity were diagnosed in 77,8% of MS patients. Clinical and metabolic MS symptoms correlated with depression severity. Adding sertraline to complex treatment was associated with hemodynamics stabilization, clinical and psychopathological symptom regression, glucose and serum lipoprotein level normalization.
Conclusion. Adding sertraline to complex treatment of MS associated with DD improved therapy effectiveness and demonstrated beneficial clinical and metabolic effects.
About the Authors
Yu. P. Uspensky
I.I. Mechnikov St. Petersburg State Medical Academy, St. Petersburg
Russian Federation
Russian Federation
E. V. Balukova
I.I. Mechnikov St. Petersburg State Medical Academy, St. Petersburg
Russian Federation
Russian Federation
References
1. Задионченко В.С. Психологические особенности и качество жизни больных артериальной гипертензией с метаболическими факторами риска. Кардиология 2002; 42(9): 15-9.
2. Оганов Р.Г., Перова Н.В., Метельская В.А. Сочетание компонентов метаболического синдрома связано с высоким риском атеросклеротических заболеваний. Кардиоваск тер профил 2004; 1: 56-9.
3. Оздоева Л.Д., Небиеридзе Д.В., Погосова Г.В. и др. Взаимосвязь факторов риска атеросклероза и тревожно-депрессивных состояний у мужчин из неорганизованной популяции. Кардиваск тер профил 2003; 1: 59-64.
4. Симаненков В.И., Успенский Ю.П. От теории психосоматической медицины – к терапевтической практике. Медлайн-экспресс 2006; 4(187): 3-7.
5. Carney RM, Freedland KE, Rich MW, et al. Depression as a risk factor for cardiac events in established coronary heart disease: a review of possible mechanisms. Ann Behav Med 1995; 17: 142-9.
6. Coodnick PJ, Henry JH, Buki VM. Treatment of depression in patient with diabetes mellitus. J Clin Psychiatry 1995; 56(4): 128-36.
7. Coodnick PJ, Kumar A, Henry JH, et al. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997; 33(2): 261-4.
8. Krook A, O Rahilly S. Bailleres Clinical Endocrinology and Metabolism. -10-th Ed. London 1996; 97-122.
9. Manuck S, Olsson G, Hjemdahl P, et al. Does cardiovascular reactivity to mental stress have prognostic value in postinfarction patient? A pilot study. Psychosom Med 1992; 54: 102-8.
10. Shapiro PA, Lesperance F, Frasure-Smith N, et al. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT trial). Am Heart J 1999; 137: 1100-06.
11. Sunita M. Depressive Symptoms Predict Hospitalization for Adolescents With Type 1 Diabetes Mellitus. Pediatrics 2005; 115; 1315-9.
Review
For citations:
Uspensky Yu.P., Balukova E.V. Depressive disorders and their correction in complex treatment of metabolic syndrome patients. Cardiovascular Therapy and Prevention. 2007;6(3):33-37. (In Russ.)
Views:
601
Email this article 
